Filing summary
Allarity Therapeutics, Inc. filed a Form 8-K reporting an event dated September 30, 2026. The report was signed October 1, 2026. The company is listed on Nasdaq under ALLR.
Business context
Under Item 8.01, the company said it provided an update on advances in its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. It stated these capabilities support clinical development of stenoparib and may broaden external partnership opportunities. The 8-K incorporates a September 30, 2026 press release as Exhibit 99.1, but the supplied filing text does not include the release’s details.
Financial information
This 8-K provides no revenue, earnings, cash flow, margin, debt, liquidity, or other financial metrics. It also reports no comparative-period financial results.
Outlook, risks, and unusual items
The filing describes potential support for stenoparib development and expanded partnership opportunities, but provides no quantified guidance, timelines, or specific partnership commitments. No risks, contingencies, or financial unusual items are detailed in the supplied text.
Key facts to verify
- Review Exhibit 99.1 for the specific DRP technology, patent, and laboratory advances and any supporting data.
- Verify the clinical-development implications for stenoparib and whether any external partnerships are concrete or prospective.
- Consult the company’s financial filings for current cash, liquidity, operating costs, and funding needs; this 8-K does not provide those figures.